✦ LIBER ✦

A randomized, double-blind, placebo-controlled, multi-center trial of the engineered human anti body to TNF (CDP571) for steroid sparing and maintenance of remission in patients with steroid-dependent Crohn's disease

✍ Scribed by Feagan, Brian G.; Sandborn, William J.; Baker, J.P.; Cominelli, F.; Sutherland, Lloyd R.; Elson, C.D.; Salberg, Bruce; Archambault, A.; Bernstein, Charles A.; Lichtenstein, G.R.; Heath, Patricia K.; Hanauer, Stephen B.

Book ID: 123034890
Publisher: Elsevier Science
Year: 2000
Tongue: English
Weight: 165 KB
Volume: 118
Category: Article
ISSN: 0016-5085
DOI: 10.1016/S0016-5085(00)84761-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A randomized, double-blind, placebo-cont

A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-α, in patients with corticosteroid-dependent Crohn's disease

✍ B. G. Feagan; W. J. Sandborn; J. P. Baker; F. Cominelli; L. R. Sutherland; C. O 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 331 KB

A randomized, double-blind, placebo-cont

A randomized, double-blind, placebo-controlled trial of the human anti-TNF-α monoclonal antibody adalimumab for the induction of remission in patients with moderate to severely active Crohn’s disease

✍ Stephen Hanauer; Milan Lukáš; Donald MacIntosh; Paul Rutgeerts; William Sandborn 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 45 KB